Ionis Pharmaceuticals Reports Financial Results and Highlights for Second Quarter 2016
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Ionis Pharmaceuticals (IONS) PT Lifted to $46 at Piper Jaffray
August 10, 2016 7:27 AM EDTPiper Jaffray analyst Joshua Schimmer reiterated an Overweight rating and raised his price target on Ionis Pharmaceuticals (NASDAQ: IONS) to $46.00 (from $36.00) following Q2 earnings and an update on its antisense pipeline.
Schimmer commented, "The company provided some color on nusinersen for the... More
Ionis Pharma (IONS) Tops Q2 EPS by 5c
August 9, 2016 8:48 AM EDTIonis Pharma (NASDAQ: IONS) reported Q2 EPS of ($0.47), $0.05 better than the analyst estimate of ($0.52). Revenue for the quarter came in at $38.5 million versus the consensus estimate of $38.52 million.
For earnings history and earnings-related data on Ionis Pharma (IONS) click here.
... More